Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2026
Sources
Institutional record
Refreshed
2026-10-07
H
Hira Imad Cheema
Sourced from institutional research profiles (UAMS TRI or ARA).
Assistant Professor
Also affiliated: Texas Tech University (2017); The University of Texas MD Anderson Cancer Center (2017); University of Arkansas Medical Center (2026); Baptist Health Foundation (2022–2023); Texas Tech University Health Sciences Center (2017)
5 h-index
23 pubs
305 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Hira Imad Cheema's research interests encompass a range of medical topics, with recent publications focusing on gastrointestinal and oncological conditions. Cheema has investigated the management of gastric neoplasms through endoscopic approaches and explored T cell subsets as predictors of response to bispecific antibody therapy in multiple myeloma. Further work includes a systematic review and meta-analysis on the prevention and treatment of bone loss and fractures in patients undergoing hematopoietic stem cell transplant, as well as a review of evidence regarding methotrexate and liver fibrosis. Other published research includes a case report on disseminated coccidioidomycosis in an HIV patient and liver injury associated with a levonorgestrel-releasing intrauterine device. Cheema has a scholarly record of 21 publications with 301 citations and an h-index of 5. Key collaborators at the University of Arkansas for Medical Sciences include Anup Kumar Trikannad, Ramya Bachu, and Tanvi H Patel, each with whom Cheema shares five co-authored publications.
Metrics
- h-index: 5
- Publications: 23
- Citations: 305
Positions
-
Assistant Professor publications 2022–2026University of Arkansas for Medical Sciences Institution web page
Selected Publications
-
CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)
-
POSTER: CLL-888: Efficacy and Safety of CAR-T Therapy in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis (2026)
-
Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)
-
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
DLL3-targeted therapy with tarlatamab in small cell lung cancer across lines of therapy: A systematic review of prospective and randomized clinical trials. (2026)
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
-
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)
-
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)
-
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)
-
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)
-
Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP) (2024)
-
Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma. (2024)
-
A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma (2024)
Collaboration Network
Top Collaborators
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
12 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
Showing 5 of 12 shared publications
Samer Al Hadidi
Southwestern Medical Center
8 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Showing 5 of 8 shared publications
Carolina Schinke
University of Arkansas Medical Center
8 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Showing 5 of 8 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
7 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 7 shared publications
Sanjay Muttineni
University of Arkansas for Medical Sciences
7 shared publications
In database
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Showing 5 of 7 shared publications
Sasya Dronavalli
University of Arkansas for Medical Sciences
7 shared publications
In database
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Showing 5 of 7 shared publications
Syed Naqvi
University of Arkansas for Medical Sciences
7 shared publications
In database
- Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma
Showing 5 of 7 shared publications
Anup Kumar Trikannad
University of Arkansas for Medical Sciences
6 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
Showing 5 of 6 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
6 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Showing 5 of 6 shared publications
Sruthi Vellanki
University of Arkansas for Medical Sciences
5 shared publications
In database
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma
- Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma
Ramya Bachu
Winthrop Rockefeller Foundation
5 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Amyloid Light-Chain (AL) Amyloidosis of the Trachea Associated With an Indolent B-cell Neoplasm
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
Trilok Shrivastava
University of Arkansas for Medical Sciences
5 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Asis Shrestha
University of Arkansas for Medical Sciences
4 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
- Minimal Residual Disease (MRD) Status and Its Impact on Clinical Outcome Is Highly Variable in Multiple Myeloma and Dependent on Molecular Subgroups Defined By Gene Expression Profiling (GEP)
- Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors
Carolina D. Schinke
University of Arkansas for Medical Sciences
4 shared publications
In database
- Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients
- Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence.
Tanvi Patel
Winthrop Rockefeller Foundation
3 shared publications
In database
- Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma.
- A Single Center Experience of T Cell Redirecting Therapy Post Stem Cell Transplantation in Relapsed Multiple Myeloma
- Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma
Similar Researchers
Based on overlapping research topics
B Barlogie
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Multiple Myeloma Research and Treatments
Naveen Yarlagadda
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Multiple Myeloma Research and Treatments
Anup Trikkanad
University of Arkansas for Medical Sciences
Medical Case Reports
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Kennedy Kuykendall
University of Arkansas for Medical Sciences
Medical Case Reports
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Medhavi Honhar
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Multiple Myeloma Research and Treatments
Immune Response and Inflammation
Logan Meurer
University of Arkansas for Medical Sciences
Medical Case Reports
Multiple Myeloma Research and Treatments
Immune Response and Inflammation